Benzinga | Apr 30, 2021 09:24AM EDT

Cancer Focus Fund To Finance Mereo's Ovarian Cancer Study With Etigilimab

* Cancer Focus Fund LP, established in collaboration with The University of Texas MD Anderson Cancer Center and Mereo BioPharma Group plc (NASDAQ: MREO), has entered into a funding agreement.

* The partnership will support a Phase 1b/2 clinical study of etigilimab combined with an anti-PD-1 antibody in clear cell ovarian cancer to be conducted at MD Anderson.

* Cancer Focus Fund will finance the study in exchange for upfront consideration of $1.5 million of Mereo shares and additional payments based on the achievement of certain milestones.

* Price Action: MREO shares are down 0.23% at $3.6 in the premarket trading on the last check Friday.